Imiquimod-d6

Imiquimod-d6

• UNSPSC Description: Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].
• Target Antigen: Autophagy; HSV; SARS-CoV; Toll-like Receptor (TLR)
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Autophagy;Immunology/Inflammation
• Field of Research: Cancer; Infection; Inflammation/Immunology
• Solubility: 10 mM in DMSO
• Smiles: NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C([2H])([2H])[2H])C([2H])([2H])[2H]
• Molecular Weight: 246.34
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[3]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60.|[4]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46.|[5]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported